Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cullinan Therapeutics Inc.

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Cullinan Management, with a price target of $36.00. According t...

JonesTrading Sticks to Their Buy Rating for Cullinan Management (CGEM)

In a report released on March 27, Laurent Daure from Kepler Capital maintained a Buy rating on Capgemini SE, with a price target of €175.00. The co...

Kepler Capital  Sticks to Their Buy Rating for Capgemini SE (0HAZ)

In a report released yesterday, Richard Nguyen from Bernstein reiterated a Buy rating on Capgemini SE, with a price target of €208.00. The company’...

Bernstein Sticks to Their Buy Rating for Capgemini SE (0HAZ)

In a report released on March 17, Laurent Daure from Kepler Capital maintained a Buy rating on Capgemini SE, with a price target of €175.00. The co...

Capgemini SE (0HAZ) Gets a Buy from Kepler Capital

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Cullinan Management yesterday and set a price target of $28.00. Thompson CFA c...

Stifel Nicolaus Sticks to Their Buy Rating for Cullinan Management (CGEM)

In a report released yesterday, Bradley Canino from Guggenheim reiterated a Buy rating on Cullinan Management, with a price target of $30.00. The c...

Guggenheim Reaffirms Their Buy Rating on Cullinan Management (CGEM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cullinan Management (CGEM – Research Report) and Med...

Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and Mediwound (MDWD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TriSalus Life Sciences (TLSI – Research Report), Cullinan Managem...

Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE)

In a report released yesterday, David Dai from UBS maintained a Buy rating on Cullinan Management, with a price target of $24.00. The company’s sha...

Current Quarter	$-0.8	Next Quarter	$-0.8
Current Year	$-3.07	Next Year	$-2.84
QoQ Growth	+0.0%	YoY Growth	+7.5%
3Y EPS CAGR	+0.0%	Target Price	$99.64
Consensus	Buy	Upside	+565.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CGEM	$14.97	+0.74%	467.88K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CGEM	$14.97	+0.7%	467.88K
3
4
5
6

CGEM

CGEM

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Cullinan Therapeutics Inc. Data in Excel

Get Cullinan Therapeutics Inc. Data in Excel